Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6748087 | 0.78 | L3MBTL1 (0.53) | ALDH1A1CYP1A2CYP2C9L3MBTL1SMN1; SMN2 | |
| SCHEMBL11599376 | 0.78 | ALDH1A1 (0.41) | ALDH1A1POLBCYP1A2CYP2C9L3MBTL1 | |
| SCHEMBL3294142 | 0.76 | PPARG (0.47) | POLBCYP1A2L3MBTL1PPARGPPARA | |
| Hydrochloric Acid SCHEMBL7054009 | 0.74 | PPARG (0.46) | POLBCYP1A2L3MBTL1PPARGPPARA | |
| SCHEMBL11545644 | 0.73 | PPARG (0.47) | ALDH1A1POLBCYP1A2CYP2C9L3MBTL1 | |
| SCHEMBL17928599 | 0.73 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1SMN1; SMN2TDP1THRB | |
| SCHEMBL24977618 | 0.71 | PPARG (0.46) | ALDH1A1POLBCYP1A2CYP2C9L3MBTL1 | |
| Glycolic Acid SCHEMBL9427710 | 0.70 | CYP2C19 (0.44) | POLBCYP1A2L3MBTL1PPARGPPARA | |
| E1501 SCHEMBL28531202 | 0.70 | ALDH1A1 (0.79) | ALDH1A1L3MBTL1PPARGPPARASMN1; SMN2 | |
| SCHEMBL13491150 | 0.70 | EPHX1 (0.56) | POLBL3MBTL1PPARGPPARAATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720445-B2 | PHENYLPROPIOLOYLOXYMETHYL ACETATE, FOR EXAMPLE; TREATING CANCER, HEMOLOGICAL DISORDERS AND INHERITED METABOLIC DISORDERS; INHIBITORS OF HISTONE DEACETYLASE | BEACON LABORATORIES, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6699902-B2 | ANTICANCER AGENTS | BEACON LABORATORIES, INC. | 2004-03-02 | — | — | US | disclosed |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | ERRANT GENE THERAPEUTICS, LLC | 2002-10-31 | — | — | US | disclosed |
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | BEACON LABORATORIES, A DELAWARE CORPORATION | 2002-08-29 | — | — | US | disclosed |
| EP-1216984-A1 | Novel acetyloxymethyl esters and methods for using same | Beacon Laboratories, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119996-A1 | Novel acetyloxymethyl esters and methods for using the same | AADAC, ACAT1, EP300 | ALDH1A1 211/4885POLB 646/4885CYP1A2 1738/4885 |
| US-20020161045-A1 | NOVEL ACETYLOXYMETHYL ESTERS AND METHODS FOR USING THE SAME | AADAC, ACAT1, EP300 | ALDH1A1 211/4885POLB 646/4885CYP1A2 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.